Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Exercises Option With Aussie Biotech Biota For Second-Gen Flu Drug

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Daiichi Sankyo has exercised its option to manufacture and market in Japan its second-generation influenza long-acting neuraminidase inhibitor CS-8958, co-owned with Autralian biotech Biota. The agreement is contingent upon successful completion of pivotal Phase III trials and approval, Biota announced March 30

You may also be interested in...



Daiichi Sankyo Lifts FY2009 Profit Forecasts, Submits NDA For Flu Inhaler Laninamivir

Daiichi Sankyo Jan. 29 lifted profit estimations for fiscal year 2009, citing favorable exchange rates for the Indian rupee against the U.S. dollar, as well as improvements in subsidiary Ranbaxy Laboratories

Daiichi Sankyo Lifts FY2009 Profit Forecasts, Submits NDA For Flu Inhaler Laninamivir

Daiichi Sankyo Jan. 29 lifted profit estimations for fiscal year 2009, citing favorable exchange rates for the Indian rupee against the U.S. dollar, as well as improvements in subsidiary Ranbaxy Laboratories

Positive Phase III Results For Relenza Follow-On Owned By Aussie Biotech Biota, Japanese Daiichi Sankyo

PERTH, Australia - Australian biotech Biota Holdings announced positive Phase III results of its Asian clinical trials for second-generation influenza treatment CS-8958, co-developed and co-owned with Daiichi Sankyo

Related Content

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel